Study to Evaluate Safety, Pharmacokinetics and Therapeutic Activity of RO6874281 as a Combination Therapy in Participants With Unresectable Advanced and/or Metastatic Renal Cell Carcinoma (RCC)

NCT03063762 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

69

Enrollment

INDUSTRY

Sponsor class

Conditions

Renal Cell Carcinoma

Interventions

DRUG: Atezolizumab
DRUG: Bevacizumab
DRUG: RO6874281

Sponsor

Hoffmann-La Roche